Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Year: 2025
Type: supplementary-materials
Abstract: Treatment-related AEs (Any grade)
Authors: Husam A. Alqaisi, David E. Cohn, Jing-Yi Chern, Linda R. Duska, Andrea Jewell, Bradley R. Corr, Ira Seth Winer, Eugenia Girda, Marta A. Crispens, Neesha C. Dhani, Ainhoa Madariaga, Robert C. Grant, Matthew Malaguti, Crystal Lee, Valerie Bowering, Horace Wong, Andrew Poothullil, Vanessa Speers, Lisa Wang, Philippe L. Bedard, John C. Brady, Andrew B. Nixon, Li Chen, Claire O’Connor, William Zamboni, Tawyna McKee, Jeffrey A. Moscow, Amit M. Oza, Stephanie Lheureux
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408535809